What the FDA labels say about taking them together
Atazanavir and methylergonovine
Atazanavir's FDA label of August 6, 2025 names methylergonovine in its contraindications section; the methylergonovine label PlainMeds reads does not name atazanavir. The atazanavir label: “Coadministration of REYATAZ with ergot derivatives is contraindicated. This is due to the potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the methylergonovine FDA label on DailyMed (effective May 1, 2026, Teva Pharmaceuticals USA, Inc.).
What does the atazanavir label say about methylergonovine?
Atazanavir label, contraindicationsDrug Class: Ergot Derivatives; Drugs within class that are contraindicated with atazanavir capsules: Dihydroergotamine, ergonovine, ergotamine, methylergonovine
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Ergot derivatives: dihydroergotamine, ergotamine, ergonovine, methylergonovine; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ ergot derivatives; Clinical Comment: Coadministration of atazanavir with ergot derivatives is contraindicated. This is due to the potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues [see ].
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the methylergonovine label say about atazanavir?
Methylergonovine's label (effective May 1, 2026) does not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methylergonovine Maleate), Teva Pharmaceuticals USA, Inc., effective May 1, 2026 (SPL set d8e4b8ed-3289-4611-8a61-2392a4bf6072), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Methylergonovine | |
|---|---|---|
| Labeled for | HIV | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $4.50 per tablet 0.2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once